Is Cochlear Limited's new hybrid device a turning point?

Access to a a new market could be great news for Cochlear and its weary shareholders

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Limited (ASX: COH), the maker of hearing aids, has received approval in the US for the launch of its hybrid hearing device, opening up a new market for the company.

Previously, Cochlear's devices were intended for those people who were profoundly deaf. Users who have hearing loss in the high frequencies, but can still hear low-frequency sounds can now get a cochlear implant to help, especially in noisy environments like restaurants. Called sensorineural hearing loss, partial loss of hearing is the most common form of hearing loss.

It opens up a totally new market for Cochlear, and the company has beaten its rivals to the punch, suggesting that it may be able to build up a strong market share, before its competitors can get a decent foothold.

What is a concern though is that while it has some big advantages, 68% of users in a trial of 50 people experiences one or more adverse events, such as low-frequency hearing loss. Six users even underwent surgery to replace the hybrid system with a standard cochlear implant. The US FDA still decided to approve the hybrid device because most users showed a significant improvement in hearing.

Cochlear could also get another boost, as it is still awaiting approval for the full set of features in its Nucleus 6 processor. The company still has a dominant market share in cochlear hearing devices globally, but concedes it lost around 10% of market share to 60% in the US over the past 1-2 years. That came after the company was forced to recall its top of the line device, tarnishing its track record of reliability.

But approval of the hybrid device and the expected approval of the fully featured Nucleus 6 processor could see Cochlear put its recent worries behind it.

As CEO Chris Roberts noted in February 2014, "One of our strategies is to continually invest. We've spent over $500 million on research and development in the last five years. Most of that benefit hasn't come back yet."

Foolish takeaway

Cochlear was the most-shorted individual stock on the ASX as at 14 March 2014, followed by News Corp (ASX: NWS), UGL Limited (ASX: UGL) and Monadelphous Group (ASX: MND). With Cochlear shares up 2.5% at lunchtime today, many of those shorters may well be forced to cover their positions in the days, weeks and months ahead. I certainly wouldn't want to be standing in front of the Cochlear train at this point in time.

Motley Fool writer/analyst Mike King owns shares in Cochlear. You can follow Mike on Twitter @TMFKinga

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »